Abstract
Bulimia nervosa (BN) and Anorexia Nervosa (AN) are currently classified as eating disorders (ED). Both disorders are the product of complex interaction between physiological and psychological and social processes; they are characterized by abnormal eating behavior. However, patients with BN differ from AN in their nutritional state and response of treatment with serotonin-selective reuptake inhibitor (SSRI) as well as frequency of comorbidity of mood and anxiety disorders. Although biological mechanisms of both BN and AN are largely unknown, excess of both feeding-stimulatory and feeding inhibitory signaling in AN have been indicated. This report reviews data that point to the hypothesis that dysregulation of monoaminergic and new peptidergic circuitry controlling food intake and energy expenditure play a major role in the eating behavior of BN.
Keywords: bulimia nervosa, eating disorder, monoamine, neuropeptide
Current Molecular Medicine
Title: Orexigenic / Anorexigenic Signals in Bulimia Nervosa
Volume: 3 Issue: 4
Author(s): Yoshiyuki Takimoto, Akio Inui, Hiroaki Kumano and Tomifusa Kuboki
Affiliation:
Keywords: bulimia nervosa, eating disorder, monoamine, neuropeptide
Abstract: Bulimia nervosa (BN) and Anorexia Nervosa (AN) are currently classified as eating disorders (ED). Both disorders are the product of complex interaction between physiological and psychological and social processes; they are characterized by abnormal eating behavior. However, patients with BN differ from AN in their nutritional state and response of treatment with serotonin-selective reuptake inhibitor (SSRI) as well as frequency of comorbidity of mood and anxiety disorders. Although biological mechanisms of both BN and AN are largely unknown, excess of both feeding-stimulatory and feeding inhibitory signaling in AN have been indicated. This report reviews data that point to the hypothesis that dysregulation of monoaminergic and new peptidergic circuitry controlling food intake and energy expenditure play a major role in the eating behavior of BN.
Export Options
About this article
Cite this article as:
Takimoto Yoshiyuki, Inui Akio, Kumano Hiroaki and Kuboki Tomifusa, Orexigenic / Anorexigenic Signals in Bulimia Nervosa, Current Molecular Medicine 2003; 3 (4) . https://dx.doi.org/10.2174/1566524033479762
DOI https://dx.doi.org/10.2174/1566524033479762 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Leptin G-2548A and Leptin Receptor Q223R Gene Polymorphisms are Differently Associated with Oxidative Process in Mexican Mestizo and Indigenous with Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Trends in Endometriosis Treatment - Review
Current Women`s Health Reviews Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis
Reviews on Recent Clinical Trials The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)
Current Pharmaceutical Design Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry Subject Index To Volume 6
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Prader-Willi Syndrome: Molecular Mechanism and Epigenetic Therapy
Current Gene Therapy Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Recent Patents on Biomarkers Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders
Current Psychiatry Reviews The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine The Anabolic Effects of Growth Hormone (GH) and GH Secretagogues on Bone Mass and Density
Medicinal Chemistry Reviews - Online (Discontinued)